Dataset Viewer
Auto-converted to Parquet Duplicate
table
stringclasses
2 values
label
stringlengths
4
13
series
stringclasses
1 value
value
int64
4
44
unit
float64
source
stringclasses
1 value
source_url
stringclasses
1 value
EMA-authorised biosimilars by year of authorisation
2019
Biosimilars
4
null
EMA, Download medicine data (file of 3 November 2026)
https://www.ema.europa.eu/en/medicines/download-medicine-data
EMA-authorised biosimilars by year of authorisation
2020
Biosimilars
8
null
EMA, Download medicine data (file of 3 November 2026)
https://www.ema.europa.eu/en/medicines/download-medicine-data
EMA-authorised biosimilars by year of authorisation
2021
Biosimilars
8
null
EMA, Download medicine data (file of 3 November 2026)
https://www.ema.europa.eu/en/medicines/download-medicine-data
EMA-authorised biosimilars by year of authorisation
2022
Biosimilars
5
null
EMA, Download medicine data (file of 3 November 2026)
https://www.ema.europa.eu/en/medicines/download-medicine-data
EMA-authorised biosimilars by year of authorisation
2023
Biosimilars
7
null
EMA, Download medicine data (file of 3 November 2026)
https://www.ema.europa.eu/en/medicines/download-medicine-data
EMA-authorised biosimilars by year of authorisation
2024
Biosimilars
17
null
EMA, Download medicine data (file of 3 November 2026)
https://www.ema.europa.eu/en/medicines/download-medicine-data
EMA-authorised biosimilars by year of authorisation
2025
Biosimilars
44
null
EMA, Download medicine data (file of 3 November 2026)
https://www.ema.europa.eu/en/medicines/download-medicine-data
EMA-authorised biosimilars by year of authorisation
2026
Biosimilars
14
null
EMA, Download medicine data (file of 3 November 2026)
https://www.ema.europa.eu/en/medicines/download-medicine-data
The eight molecules with the most authorised biosimilars
Denosumab
Biosimilars
30
null
EMA, Download medicine data (file of 3 November 2026)
https://www.ema.europa.eu/en/medicines/download-medicine-data
The eight molecules with the most authorised biosimilars
Aflibercept
Biosimilars
12
null
EMA, Download medicine data (file of 3 November 2026)
https://www.ema.europa.eu/en/medicines/download-medicine-data
The eight molecules with the most authorised biosimilars
Ustekinumab
Biosimilars
11
null
EMA, Download medicine data (file of 3 November 2026)
https://www.ema.europa.eu/en/medicines/download-medicine-data
The eight molecules with the most authorised biosimilars
Pegfilgrastim
Biosimilars
11
null
EMA, Download medicine data (file of 3 November 2026)
https://www.ema.europa.eu/en/medicines/download-medicine-data
The eight molecules with the most authorised biosimilars
Adalimumab
Biosimilars
10
null
EMA, Download medicine data (file of 3 November 2026)
https://www.ema.europa.eu/en/medicines/download-medicine-data
The eight molecules with the most authorised biosimilars
Trastuzumab
Biosimilars
8
null
EMA, Download medicine data (file of 3 November 2026)
https://www.ema.europa.eu/en/medicines/download-medicine-data
The eight molecules with the most authorised biosimilars
Bevacizumab
Biosimilars
8
null
EMA, Download medicine data (file of 3 November 2026)
https://www.ema.europa.eu/en/medicines/download-medicine-data
The eight molecules with the most authorised biosimilars
Ranibizumab
Biosimilars
8
null
EMA, Download medicine data (file of 3 November 2026)
https://www.ema.europa.eu/en/medicines/download-medicine-data

Biosimilars authorised by the EMA, by year and molecule

crida studio count of the 152 biosimilars for human use authorised in the public EMA file of 3 November 2026. Biosimilars by year of authorisation and by molecule.

The EMA's public medicines file lists 152 authorised biosimilars for human use, based on our download of 3 November 2026. They cover 27 molecules and 41 different holders. 44 of 152 were authorised in 2025, and 26 of those are denosumab. If you sell equipment, consumables or manufacturing services, this is a public list of potential customers and of the molecules where things are moving.

Published by crida studio (Caldes de Malavella, Girona, Spain) on 2026-11-03, last updated on 2026-11-03. Web page with the charts, the analysis and the other languages: https://www.crida.studio/en/insights/guides/ema-approved-biosimilars-2026/

Files

  • biosimilars-autoritzats-ema-2026-en.csv

Period covered: 2006/2026.

Geographic coverage: European Union.

Method

We downloaded the file Medicines output, medicines report from the EMA's Download medicine data page. The EMA generated it on 3 November 2026 at 6 am and we downloaded it the same day. We kept the rows with category Human and Biosimilar Yes. That gives 196 rows, and 152 have the status Authorised.

We counted holders without regard to upper or lower case. For the yearly count we used the marketing authorisation date. One authorised medicine, Pavblu, has no such date in the file and is left out of the yearly count, which therefore adds up to 151.

There are limits. The EMA itself says it evaluates the majority of biosimilar applications in the EU, not all of them. We count authorisations, not sales or production volume. One molecule can have several brand names from the same holder.

Sources

Licence

CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Credit crida studio and link to https://www.crida.studio/en/insights/guides/ema-approved-biosimilars-2026/. The source data keep the terms of each source.

How to cite

crida studio (2026). Biosimilars authorised by the EMA, by year and molecule. https://www.crida.studio/en/insights/guides/ema-approved-biosimilars-2026/

Contact

hola@crida.studio

Also on Harvard Dataverse

The same dataset, with a permanent identifier: https://doi.org/10.7910/DVN/AV52CG

More open data from crida studio: https://github.com/cridastudio/open-data

Downloads last month
49